Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/14815
ACTIVE CYTOMEGALOVIRUS (CMV) INFECTION IN LIVER RECIPIENTS IN A HIGH CMV SEROPREVALENCE REGION - OUTCOMES AND THE USE OF ANTIGENEMIA
Author
Affilliation
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Hospital Português. Serviço de Transplante Hepático. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil
Abstract
Cytomegalovirus (CMV) is the most frequent viral infection in liver recipients, acting as immunomodulatory factor for
other opportunistic infections and rejection. We assessed the outcomes of CMV infection in liver recipients in a high
CMV seroprevalence region and the use of antigenemia for the diagnosis of CMV syndrome. Between March 2007
and April 2009, 44 liver recipients collected 344 samples for CMV antigenemia. Defi nition of active CMV infections
used literature criteria. Recipients’ outcomes [CMV syndrome, Hepatitis C Virus (HCV) recurrence, rejection and
mortality] were analyzed. Performance of antigenemia for the diagnosis of CMV syndrome was assessed by the area
under the Receiver Operating Curve (AUROC) of 52 positive samples, representing 24 recipients. CMV serology was
positive (R+) in 90.9% of liver recipients. CMV syndrome occurred in 18 (40.9%) recipients. CMV negative serology
(R-) recipients had lower disease-free time, as well as lower one-year and four-year survival rates (p = 0.022 and p =
0.004, respectively). HCV+ recipients presented CMV-associated indirect eff ects and had a tendency to lower fouryear
survival rate (p=0.089). Th e AUROC for CMV syndrome was 0.745 (95% CI 0.606 to 0.856, p = 0.006), with a
cut-off of more than 8 positive cells/200,000 leukocytes, (sensitivity of 88.9% and specifi city of 74.4%). CMV infection
is associated to morbidity and lower survival rates in liver recipients in a high CMV seroprevalence region. Using
antigenemia, the cut-off for diagnosing CMV syndrome was higher than 8 positive cells/200,000 leukocytes, with an
appropriated performance through its accuracy.
Share